5

10

Abstract

The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (D):

$$\begin{pmatrix} C \\ W^2 \end{pmatrix} - V^2 - \begin{pmatrix} B \\ W^2 \end{pmatrix} - V^1 - \begin{pmatrix} A \\ W^1 \end{pmatrix} - X - Y$$
 (I)

wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a single bond, $\cdot O \cdot$, $\cdot CH_2 \cdot$, $\cdot NH \cdot$, $\cdot SO \cdot$ and the like, Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl and the like, each of V^1 and V^2 is a single bond, $\cdot O \cdot$, $\cdot NH \cdot$, $\cdot OCH_2 \cdot$ and the like,

a prodrug, pharmaceutically acceptable salt or solvate thereof.